XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring
9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring

17. Restructuring

 

On February 13, 2023, the Company announced the topline results for the Phase 2b study of FX-322 (FX-322-208) which failed to achieve its primary efficacy endpoint of an improvement in speech perception. As a result, the Company also announced that it would be discontinuing the FX-322 and FX-345 hearing development programs and focusing resources on its remyelination in MS development program. This restructuring resulted in a 55% reduction in the Company's workforce.

 

In the nine months ended September 30, 2023, the Company incurred $4,329 in restructuring-related expenses. The total restructuring charges consist of accelerated depreciation expense of $360, accelerated hearing program expense of $129, and severance and other benefit-related costs of $3,840.

 

During the nine months ended September 30, 2023, the following restructuring-related charges were included in the Consolidated Statement of Operations:

 

 

Severance and other benefit-related costs

 

 

Accelerated depreciation charges

 

 

Accelerated hearing program charges

 

 

Total

 

Research and development

$

2,138

 

 

$

360

 

 

$

129

 

 

$

2,627

 

General and administrative

 

1,702

 

 

 

 

 

 

 

 

 

1,702

 

Total

$

3,840

 

 

$

360

 

 

$

129

 

 

$

4,329

 

 

At September 30, 2023, the liability for the restructuring is classified as current and included in accrued expenses in the Consolidated Balance Sheets.

 

 

Accelerated hearing program charges

 

 

Severance and other benefit-related costs

 

 

Total

 

Liability balance as of December 31, 2022

$

-

 

 

$

-

 

 

$

-

 

Net charges

 

6

 

 

 

916

 

 

 

922

 

Liability balance as of September 30, 2023

$

6

 

 

$

916

 

 

$

922